Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct...

Full description

Bibliographic Details
Main Authors: Pedro Nazareth Aguiar Jr., Pui San Tan, Sarah Simko, Carmelia Maria Noia Barreto, Bárbara de Souza Gutierres, Auro del Giglio, Gilberto de Lima Lopes Jr
Format: Article
Language:English
Published: Instituto Israelita de Ensino e Pesquisa Albert Einstein
Series:Einstein (São Paulo)
Subjects:
Cost-benefit analysis
Drug therapy/economy
Hormone therapy/economy
Prostatic neoplasms/drug therapy
Drug costs
Placebos
Public Health
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000200300&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000200300&lng=en&tlng=en

Similar Items